Metabolomic Study in Huntington's Disease (METABO-HD)

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT03296176
• Date of registration: 15/09/2017
• Prospective Registration: Yes
• Primary sponsor: University Hospital, Angers
• Public title: Metabolomic Study in Huntington's Disease (METABO-HD)
• Scientific title: Metabolomic Study in Huntington's Disease
• Date of first enrolment: October 9, 2017
• Target sample size: 150
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT03296176
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France

Contacts

• Name: Christophe Verny, PU-PH
• Affiliation: University Hospital, Angers

• Name: Christophe Verny, PU-PH

• Name: VERNY

Key inclusion & exclusion criteria

Inclusion Criteria:

For all groups:

- age between 20 and 70 years

- signature of the informed consent

- covered by social security

For presymptomatic group:

- positive genetic test with CAG repeat length = 37 in HTT gene

- Unified Huntington Disease Rating Scale = 5

For symptomatic group:

- positive genetic test with CAG repeat length = 37 in HTT gene

- The Unified Huntington's Disease Rating Scale motor score = 6

- The Total Functional Capacity score = 11

Exclusion Criteria for all groups:

- participation in another therapeutic trial (3 months exclusion period)

- pregnancy and breastfeeding

- persons deprived of their liberty by judicial or administrative decision



Age minimum: 20 Years
Age maximum: 70 Years
Gender: All

Health Condition(s) or Problem(s) studied

Huntington Disease

Intervention(s)

Biological: blood sample

Primary Outcome(s)

metabolite mass [Time Frame: at baseline]

Secondary ID(s)

49RC17_0086

Source(s) of Monetary Support

Please refer to primary and secondary sponsors